Corporate Collaboration and Regulatory Milestones in Oncology and Autoimmune Therapeutics
Daiichi Sankyo Co., Ltd. has entered a significant partnership with AstraZeneca regarding the oncology drug Enhertu (trastuzumab deruxtecan). The collaboration, which began in 2019, involves joint development and commercialisation of Enhertu worldwide, with Daiichi Sankyo retaining exclusive rights in Japan.
The drug has been recommended for approval in the European Union by the Committee for Medicinal Products for Human Use (CHMP) as a monotherapy for patients with residual invasive disease following neoadjuvant treatment for HER2‑positive early breast cancer. The recommendation follows data from the Phase III DESTINY‑Breast05 trial, which demonstrated a substantial reduction in the risk of invasive disease recurrence or death compared with the current standard of care. Enhertu is already approved in the United States and several other regions for the same indication and has a broader portfolio of approvals in other HER2‑targeted malignancies.
In the same reporting period, Daiichi Sankyo also received positive regulatory opinions in Europe for its drug Klygefa (suvorelin), an antibody targeting generalized myasthenia gravis, reflecting the company’s expanding focus beyond oncology. While the Enhertu approval is a milestone for the company’s oncology strategy, the Klygefa opinion underscores a diversification of therapeutic areas.
The CHMP recommendation for Enhertu is expected to influence the European market for adjuvant HER2‑positive breast cancer treatment, potentially expanding the available therapeutic options for patients who remain at high risk of recurrence after surgery. Daiichi Sankyo’s role in manufacturing and supply for Enhertu will support the commercial rollout, while AstraZeneca’s sales network is positioned to drive market penetration. The joint development agreement also includes shared responsibility for further clinical development, including combination studies with other immunotherapies and exploration of earlier lines of treatment.
Overall, the recent approvals and regulatory endorsements highlight Daiichi Sankyo’s active engagement in advancing both its oncology and non‑oncology portfolios, positioning the company for continued growth within the competitive pharmaceutical landscape.
